Altimmune Files Definitive Proxy Statement for Annual Meeting

TL;DR

Altimmune's proxy statement is out for the Sept 26 meeting - shareholders vote on company direction.

AI Summary

Altimmune, Inc. filed its definitive proxy statement (DEF 14A) on August 15, 2024, for its annual meeting on September 26, 2024. The filing concerns the solicitation of proxies from shareholders regarding matters to be voted on at the meeting. Altimmune, Inc. is a biopharmaceutical company focused on developing treatments for liver disease and obesity.

Why It Matters

This filing provides shareholders with crucial information about the company's governance and the proposals they will vote on, impacting the future direction and leadership of Altimmune, Inc.

Risk Assessment

Risk Level: medium — Proxy statements are routine filings, but the specific proposals and shareholder votes can significantly impact a company's future, especially in the volatile biotech sector.

Key Numbers

• 20240926 — Annual Meeting Date (Shareholders will vote on proposals at this date.)
• 20240815 — Filing Date (The definitive proxy statement was filed on this date.)

Key Players & Entities

• Altimmune, Inc. (company) — Registrant
• 20240815 (date) — Filing Date
• 20240926 (date) — Meeting Date
• PHARMATHENE, INC (company) — Former Company Name
• HEALTHCARE ACQUISITION CORP (company) — Former Company Name

FAQ

Key Financial Figures

• $0.0001 — f record of our Common Stock, par value $0.0001 per share (" Common Stock "), at the cl

Filing Documents

• tmb-20240926xdef14a.htm (DEF 14A) — 743KB
• tmb-20240926xdef14a_a001.jpg (GRAPHIC) — 5KB
• tmb-20240926xdef14a_a002.jpg (GRAPHIC) — 5KB
• tmb-20240926xdef14a_a003.jpg (GRAPHIC) — 7KB
• tmb-20240926xdef14a_a009.jpg (GRAPHIC) — 29KB
• tmb-20240926xdef14a_a010.jpg (GRAPHIC) — 29KB
• tmb-20240926xdef14a_bg001.jpg (GRAPHIC) — 199KB
• tmb-20240926xdef14a_bg002.jpg (GRAPHIC) — 163KB
• 0001326190-24-000038.txt ( ) — 1346KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21 EXECUTIVE OFFICERS 23

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 33 OTHER MATTERS 34 i Table of Contents Altimmune, Inc. 910 Clopper Road, Suite 201S Gaithersburg, Maryland 20878 PROXY STATEMENT FOR THE 2024 ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON THURSDAY, SEPTEMBER 26, 2024 GENERAL INFORMATION This Proxy Statement is furnished in connection with a solicitation of proxies by the Board of Directors (the " Board " or " Board of Directors ") of Altimmune, Inc., a Delaware corporation (" Altimmune ," the " Company ," " we " or " our "), to be used at our 2024 Annual Meeting of Stockholders (the " Annual Meeting ") scheduled for Thursday, September 26, 2024, at 8:30 a.m., Eastern Daylight Time. The Annual Meeting will be held virtually at https://www.cstproxy.com/altimmune/2024, where you will be able to vote electronically and submit questions. We invite you to attend the Annual Meeting virtually to vote on the proposals described in this proxy statement. You will need the 12-digit control number included with these proxy materials to attend the annual meeting. This Proxy Statement, the accompanying Notice of Annual Meeting of Stockholders and proxy card are first being mailed to stockholders on or about August 19, 2024. Whenever we refer in this Proxy Statement to the "Annual Meeting," we are also referring to any meeting that results from any postponement or adjournment of the September 26, 2024 meeting. Holders of record of our Common Stock, par value $0.0001 per share (" Common Stock "), at the close of business on August 12, 2024 (the " Record Date ") are entitled to notice of, and to vote at, the Annual Meeting. On that date, there were 71,070,951 shares entitled to be voted. We encourage you to vote your shares, either by voting at the Annual Meeting or by granting a proxy (i.e., authorizing someone to vote your shares). If you vote via the Internet or telephone or execute the attached paper proxy card, the individ

View Full Filing

View this DEF 14A filing on SEC EDGAR